Tasigna is owned by Novartis.
Tasigna contains Nilotinib Hydrochloride.
Tasigna has a total of 14 drug patents out of which 0 drug patents have expired.
Tasigna was authorised for market use on 29 October, 2007.
Tasigna is available in capsule;oral dosage forms.
Tasigna can be used as treatment of newly diagnosed philadelphia chromosome positive chronic myeloid leukemia (ph + cml); treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml), a method for the treatment of leukemias, treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml), treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation.
The generics of Tasigna are possible to be released after 07 October, 2032.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(3 months from now) | |
US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(3 years from now) | |
US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(5 years from now) | |
US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7169791
(Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(9 months from now) | |
US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(3 years from now) | |
US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(3 years from now) | |
US8415363
(Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(3 years from now) | |
US8501760
(Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(3 years from now) | |
US8389537
(Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(3 years from now) | |
US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(4 years from now) | |
US8293756
(Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(4 years from now) | |
US8163904
(Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(5 years from now) | |
US9061029
(Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 23, 2028 |
Pediatric Exclusivity (PED) | Sep 22, 2025 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 29 October, 2007
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); A method for the treatment of leukemias; Treatment of newly diagnosed philadelphia chromosome positive chronic myeloid ...
Dosage: CAPSULE;ORAL
28
United States
18
European Union
12
Japan
11
Korea, Republic of
10
Australia
10
China
9
Spain
8
Russia
8
Poland
8
Canada
7
Taiwan, Province of China
6
Denmark
6
Hong Kong
6
Slovenia
6
Portugal
6
Cyprus
6
Peru
6
New Zealand
5
Israel
5
South Africa
5
Mexico
5
Argentina
5
Brazil
5
Croatia
5
Malaysia
5
Ecuador
4
Jordan
4
Morocco
4
Norway
4
Tunisia
3
Hungary
3
Colombia
3
Singapore
3
Guatemala
2
Austria
2
Cuba
2
San Marino
2
Chile
2
RS
2
United Kingdom
2
EA
1
Lithuania
1
Philippines
1
Uruguay
1
Costa Rica
1
Germany
1
Honduras
1
Georgia
1
Ukraine
1
Nicaragua
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic